Alpha Mark Advisors, LLC Moderna, Inc. Transaction History

Alpha Mark Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 19, 2024	SELL	$69.51 - $104.43 $3,475 - $5,221	-50 Reduced 74.63%	17 $2,000
Q3 2023 Oct 31, 2023	BUY	$96.41 - $126.61 $1,638 - $2,152	17 Added 34.0%	67 $7,000
Q2 2023 Jul 28, 2023	BUY	$118.5 - $160.53 $5,925 - $8,026	50 New	50 $6,000
Q2 2022 Aug 11, 2022	SELL	$117.13 - $176.59 $23,426 - $35,318	-200 Reduced 72.73%	75 $11,000
Q1 2022 May 02, 2022	SELL	$126.46 - $235.05 $17,704 - $32,907	-140 Reduced 33.73%	275 $47,000
Q4 2021 Feb 09, 2022	BUY	$225.82 - $368.51 $14,452 - $23,584	64 Added 18.23%	415 $105,000
Q3 2021 Nov 05, 2021	BUY	$221.9 - $484.47 $221 - $484	1 Added 0.29%	351 $135,000
Q2 2021 Aug 06, 2021	SELL	$129.91 - $234.98 $22,734 - $41,121	-175 Reduced 33.33%	350 $82,000
Q1 2021 Apr 29, 2021	SELL	$109.18 - $185.98 $24,019 - $40,915	-220 Reduced 29.53%	525 $69,000
Q4 2020 Feb 01, 2021	BUY	$65.74 - $169.86 $42,402 - $109,559	645 Added 645.0%	745 $77,000
Q3 2020 Nov 06, 2020	BUY	$54.34 - $94.85 $3,260 - $5,691	60 Added 150.0%	100 $7,000
Q2 2020 Aug 10, 2020	BUY	$29.67 - $80.0 $1,186 - $3,200	40 New	40 $3,000

954

241M

10.6M

18.7M

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Mark Advisors, LLC with notifications on news.